Join
Live feed
·
PRReleasevia Quantisnow
Ocean Biomedical Inc. logo

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

ByQuantisnow·Wall Street's wire, on your screen.
OCEA· Ocean Biomedical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCEA (Ocean Biomedical Inc.) and more on Quantisnow.